MYL6

Across TCGA pan-cancer cohorts, MYL6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MYL6 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MYL6 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MYL6 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, GBM, and LSCC are the cancer types where MYL6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.713	0.404	.004	9	view →
GBM	DFS	Quartile	All	0.248	0.550	.001	8	view →
LSCC	DFS	Median	II,III,IV	0.680	0.866	.027	5	view →
HNSC	OS	Quartile	II,III,IV	0.570	0.800	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MYL6–PDAC (OS)

Open the PDAC breakdown →